The closing price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) was $53.81 for the day, down -3.76% from the previous closing price of $55.91. In other words, the price has decreased by -$2.10 from its previous closing price. On the day, 808979 shares were traded.
Ratios:
Our analysis of APLS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.50 and its Current Ratio is at 3.10. In the meantime, Its Debt-to-Equity ratio is 0.57 whereas as Long-Term Debt/Eq ratio is at 0.54.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on February 05, 2024, Upgraded its rating to Buy and sets its target price to $80 from $68 previously.
On November 09, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $74.Goldman initiated its Buy rating on November 09, 2023, with a $74 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 01 ’24 when Sullivan Timothy Eugene sold 4,000 shares for $58.66 per share. The transaction valued at 234,640 led to the insider holds 93,338 shares of the business.
Dunlop A. Sinclair sold 18,681 shares of APLS for $1,068,161 on Mar 19 ’24. The Director now owns 173,998 shares after completing the transaction at $57.18 per share. On Mar 18 ’24, another insider, DeLong Mark Jeffrey, who serves as the Chief Business & Strat Officer of the company, sold 9,913 shares for $56.90 each. As a result, the insider received 564,050 and left with 54,693 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 6.48B and an Enterprise Value of 6.24B. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.36 while its Price-to-Book (P/B) ratio in mrq is 33.07. Its current Enterprise Value per Revenue stands at 15.74 whereas that against EBITDA is -12.61.
Stock Price History:
Over the past 52 weeks, APLS has reached a high of $94.75, while it has fallen to a 52-week low of $19.83. The 50-Day Moving Average of the stock is 62.28, while the 200-Day Moving Average is calculated to be 54.03.
Shares Statistics:
APLS traded an average of 1.50M shares per day over the past three months and 972.12k shares per day over the past ten days. A total of 119.56M shares are outstanding, with a floating share count of 98.84M. Insiders hold about 18.03% of the company’s shares, while institutions hold 91.85% stake in the company. Shares short for APLS as of Mar 15, 2024 were 10.59M with a Short Ratio of 7.06, compared to 10.27M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.78% and a Short% of Float of 10.19%.
Earnings Estimates
The firm’s stock currently is rated by 11 analysts. On average, analysts expect EPS of -$0.54 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.88, while EPS last year was -$1.56. The consensus estimate for the next quarter is -$0.37, with high estimates of $0.09 and low estimates of -$0.6.
Analysts are recommending an EPS of between $0.46 and -$2.23 for the fiscal current year, implying an average EPS of -$1.2. EPS for the following year is $1.2, with 11 analysts recommending between $2.28 and $0.13.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 13 analysts. It ranges from a high estimate of $178.58M to a low estimate of $130.45M. As of the current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $44.85M, an estimated increase of 260.70% from the year-ago figure. For the next quarter, 13 analysts are estimating revenue of $188.48M, an increase of 168.30% less than the figure of $260.70% in the same quarter last year. There is a high estimate of $228.28M for the next quarter, whereas the lowest estimate is $161.39M.
A total of 13 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $919.78M, while the lowest revenue estimate was $712.95M, resulting in an average revenue estimate of $796.83M. In the same quarter a year ago, actual revenue was $396.59M, up 100.90% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $1.18B in the next fiscal year. The high estimate is $1.57B and the low estimate is $946.04M. The average revenue growth estimate for next year is up 48.40% from the average revenue estimate for this year.
